Efficacy and Safety of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
By incorporating the most recent data and the newly published studies, this updated meta-analysis offers a clearer understanding of immune checkpoint inhibitors and reinforces their advantage over other therapeutic options in the treatment of hepatocellular carcinoma. Continued research is encouraged that will further validate these findings.
Authors
- Hamza Ashraf (ORCID: https://orcid.org/0009-0007-9121-6091)
- Ahmad O. Noor (ORCID: https://orcid.org/0000-0002-2842-1750)
- Javeeria Arshad (ORCID: https://orcid.org/0009-0008-7979-1429)
- Azeem Saeed
- Aanusha Ghouri (ORCID: https://orcid.org/0000-0003-0743-9844)
- Minahil Ansir Ali
- Hafiza K. Shahid
- Mishal Asif
- Maaz Khan
- Moeaza R. Rizvi
- Muhammad H.A. Khalid
- Muhammad R. Paracha
- Talha Abbas
- Muhammad A.B. Naeem
Institutions
- Fatima Jinnah Medical University (PK)
- Allama Iqbal Medical College (PK)
- Anne Arundel Medical Center (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1097/coc.0000000000001278
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00